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Multiple isozymes of Ca2+/phospholipid-dependent protein kinase (PKC) were isolated from the rat ventral prostate. The enzyme exists mainly 
as type II @I), and type III (a) forms, and it is possible that type II isozyme may comprise the subspecies /I, and 8,. The total and specific activities 
of prostatic PKC isoforms were reduced in castrated animals; this decrease was specific since administration of androgens to castrated animals 
reversed such a decline. Also, there was a differential response to androgen deprivation so that type III isozyme declined at a faster rate than that 
of type II. Thus, our studies show for the first time that PKC of the rat ventral prostate comprises multiple isozymes, and that the activity of 
these various forms are differentially regulated by androgens. 
Ca2+/phospholipid-dependent protein kinase; CaZf/phospholipid-dependent protein kinase isozyme; Ventral prostate; Androgen 
1. INTRODUCTION 2. MATERIALS AND METHODS 
It is well known that the growth and function of the 
rat ventral prostate is under strict androgenic control, 
and therefore it is considered an excellent model for in- 
vestigating the mechanism of androgen action [l]. The 
prostate gland produces several growth factors such as 
prostate-derived growth factor, basic fibroblast growth 
factor, etc. [2-51 and their production is also reported 
to be under androgenic controls [6,7]. Several of these 
growth factors elicit their physiological responses via 
receptor-mediated hydrolysis of inositol phospholipids 
which is essential for the activation of Ca+/phospho- 
lipid-dependent protein kinase (PKC) [8,9]. More 
recently, other steroid hormones such as estrogen [lo], 
and vitamin D3 [l l] were found to activate PKC direct- 
ly. Thus, it was hypothesized that PKC may also be 
under androgenic regulation in the prostate. To this 
end, the present work was undertaken to investigate the 
androgenic regulation of PKC isozymes in the rat ven- 
tral prostate. Our results indicate that the rat ventral 
prostatic PKC exists in multiple forms (cu, pi, and ,&). 
The total and specific activities of prostatic PKC 
isozymes were decreased in castrated animals. Further- 
more, the various forms of PKC were found to be dif- 
ferentially regulated by androgens. 
2.1. Partial purification and separation of PKC isovmes 
2.1.1. Buffers 
Buffer A=20 mM Tris/HCl, pH 7.5, 2 mM EDTA, 10 mM 
EGTA, and 10 mM ,&mercaptoethanol @vlE), buffer B = 20 mM 
Tris/HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, protease in- 
hibitors, and 10 mM @ME; and buffer C= 20 mM potassium 
phosphate, 0.5 mM EGTA, 10 mM,&ME, and 10% glycerol. All buf- 
fer solutions contained the following protease inhibitors: leupeptin 
(5.0 fig/ml); benzamidine (0.5 mM); and phenylmethylsulfonyl 
fluoride (0.5 mM). 
The ventral prostates from fifty 3-month-old sham-operated (con- 
trol) or orchiectomized rats (20-25 g) were pooled, and a 20% 
homogenate was prepared in buffer A containing 0.32 M sucrose. 
Nuclei were removed by low-speed centrifugation and the superna- 
tant was centrifuged at 105 OOOxg for 60 min. The pellet (mem- 
branous fraction) was extracted with buffer A containing 0.1% 
NP-40 detergent on ice for 30 min and centrifuged for 60 min at 
105OOOxg. The two supernatants were pooled and applied to a 
DEAE-52 column (1.6x 10 cm) pre-equilibrated in buffer B. After 
washing the column thoroughly with buffer B, a 300-ml gradient of 
NaCl (O-400 mM) in buffer B was applied to the column. Fractions 
containing PKC activity were pooled, and applied directly to a DNA- 
grade hydroxyapatite (Bio-Rad) column (0.9x 10 cm) pre- 
equilibrated in buffer C. The column was washed with buffer C and 
a 200-ml gradient of potassium phosphate (20-250 mM) in buffer C 
was applied to the column. Fractions were assayed for PKC activity. 
Isozymes were well-separated on this column and the active fractions 
under each peak were pooled and assayed for protein, DNA, and 
PKC activity. 
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2.2. Determination of protein kinase C activity: 
Measurement of enzyme activity was carried out at 30°C for 0, 3, 
and 6 min after addition of the enzyme according to published pro- 
cedure /2]. The reaction mixture consisted of 20 mM Tris/HCl buf- 
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fer, pH 7.5, 10 mM magnesium acetate, 0.1 mM [y-3ZP]ATP (spec. 
act. = 100-500 dpm/pmol), 1 mM EGTA, 1.2 mM CaClr, 0.04% 
NP-40, 50&m] PtdSer, lO,ug/ml Diolein, 1 mg/ml histone Hl, and 
protein kinase C. PKC activity was expressed as nmol “P incor- 
porated in histone/h per mg of enzyme protein in the presence of 
Ca’+/phospholipid minus that in the absence of Ca’+/phospholipid. 
2.3. Other methods 
Rats were orchiectomized as described by us [ 121 and examined 1, 
2, 3, and 7 days post-orchiectomy. Sham-operated animals served as 
normal intact controls. Protein and DNA were assayed as described 
by us earlier [13,14]. 
3. RESULTS AND DISCUSSION 
A profile of PKC isozymes from prostatic extract 
(cytosol + membrane) fractionated on hydroxyapatite 
column is shown in Fig.1. It appears that multiple 
forms of PKC are present in the rat ventral prostate. 
Two major peaks of PKC with almost equal activities 
were present, and both peaks were stimulated up to 
20-fold in the presence of Ca2+/phospholipids. Type II 
(isozyme p), and Type III (isozyme cu) forms of PKC 
were eluted at 100 mM and 150 mM potassium 
phosphate, respectively. There was also indication of 
an additional isozyme located between peaks I and II 
(which is eluted at 125 mM potassium phosphate). 
Also, the absence of Type I or isozyme y (which is 
eluted from the column at 70 mM potassium 
phosphate) is consistent with previous reports on its 
specific association with the central nervous system [ 11. 
The effect of androgen withdrawal for periods of 1, 2, 
3, and 7 days on the distribution and activity of the 
various PKC isozymes is shown in Fig. IA-D and Table 
I. A modest decline (lo-15%) in total and specific ac- 
tivities in both peaks I and II of PKC was observed 24 
h after castration (Table I, and Fig.lA). However, the 
total as well as specific activities of PKC isozymes were 
significantly reduced in the prostatic tissue from rats 2 
days or longer after castrated, when compared with 
sham-operated animals. For example, in the prostatic 
tissue from rats 2 days after castration, the total and 
specific activities of peak II declined by 54% while that 
of peak I decreased by 30% as a result of castration 
(Table I and Fig. IB). Thus, it appears that there was 
a differential effect of androgen withdrawal on the ac- 
tivities of PKC isozymes so that type III isozyme is 
more sensitive to androgen deprivation than type II. At 
3 and 7 days post-orchiectomy, the total and specific 
activities of both peaks I and II were further reduced as 
compared with controls (Table I and Fig.lC, D). For 
example, the specific activity of peaks I and II declined 
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Fig.1. Hydroxyapatite column chromatographic profile of PKC isolated from rat ventral prostate. Prostatic tissue from sham-operated or 
castrated rats was used to isolate PKC isozymes. Column chromatographic profiles of PKC isozymes from prostates of rats 24 h (A), 48 h (B), 
72 h (C), and 196 h (D) post-castration are shown. PKC isolated from sham-operated rats served as the control in each panel. 
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Table I 
Total and specific activity of PKC isozymes of rat ventral prostate: effects of castration 
Days after DNA 
castration (mg) 
0 16.3 (lOO)* 
1 16.2 (99) 
2 14.7 (90) 
3 13.1 (80) 
7 6.5 (40) 
Total activity 
@mol’*P/h) 
PK I PK II 
418 (100) 683 (100) 
345 (83) 596 (87) 
254 (61) 308 (45) 
158 (38) 174 (26) 
65 (16) 54 (8) 
Spec. act. 
&mo13*P/mg DNA per h) 
PK I PK II 
25.6 (100) 41.9 (100) 
21.3 (83) 36.8 (88) 
17.3 (68) 21.0 (50) 
12.1 (47) 13.3 (32) 
10.0 (40) 8.3 (20) 
* Values in parentheses are expressed as % of the corresponding control. Data are representative of three dif- 
ferent experiments. 50 rats were used for each time point. Controls are sham-operated rats. Total PKC activity 
is activity per 50 prostates. Injection of SCX-DHT dissolved in sesame oil (1 mg/lOO g b. wt.) into castrated rats 
maintained the total and specific activity of peaks I and II of PKC at the normal levels 
by 60% and 70%, respectively, at 3 days. The total ac- 
tivity for both peaks declined to 30-40% of that of 
control. The administration of 1 mg of Sa-dihydro- 
testosterone per 100 g of body weight to previously 
castrated rats reversed the decline in these activities, 
suggesting that the aforementioned changes in prostatic 
PKCs are functions of alteration in the androgenic 
status in the animals. These results document for the 
first time the regulation of PKC isozymic pattern by an- 
drogens. In this regard, it was reported recently that 
other steroids also regulate PKC activity [lO,ll]. For 
example, chronic treatment of ovarectomized rats or 
normal pituitary cells with estrogens significantly in- 
creased the total PKC activity. The amounts of both 
soluble and membrane-bound forms of the enzyme 
were equally increased by the active but not by the inac- 
tive estrogen analogue [lo]. Also, it was reported that 
1,25-(OH)2 D3 induced differential induction of PKC 
isozymes in HL-60 cells where the steroid enhanced the 
transcriptional activity of the gene for PKC,8 and to a 
lesser extent the gene for PKCa [ 111. It is noteworthy 
that this induction was independent of phospholipid 
hydrolysis and diacylglycerol generation. This is impor- 
tant since steroid hormone receptors are not localized 
at the cell surface and therefore are not coupled to 
phospholipid turnover. Whether androgens regulate 
the PKC isozyme pattern in a similar manner to vitamin 
Ds and estrogens as described above, or that androgens 
differentially activate existing PKC isozymes awaits 
further investigation. 
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